Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Portfolio Pulse from Vandana Singh
Ionis Pharmaceuticals and Biogen have decided to terminate the development of BIIB105 for ALS due to lack of efficacy in reducing neurodegeneration markers. Additionally, Biogen has chosen not to license Ionis' ION582 for Angelman syndrome, despite positive safety and functional improvement data. Ionis will independently advance ION582. Both companies' stocks have declined following the news.
May 16, 2024 | 4:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biogen's stock fell 2.12% after announcing the termination of BIIB105 development for ALS and deciding not to license ION582 for Angelman syndrome. The lack of efficacy in BIIB105 and opting out of ION582 licensing are seen as negative developments.
The termination of BIIB105 due to lack of efficacy and the decision not to license ION582 are negative developments for Biogen, leading to a decline in stock price. These decisions reflect challenges in their neurology-focused pipeline.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Ionis Pharmaceuticals' stock dropped 5.19% following the announcement that BIIB105 development for ALS is terminated and Biogen will not license ION582 for Angelman syndrome. Ionis will advance ION582 independently.
The termination of BIIB105 and Biogen's decision not to license ION582 are significant setbacks for Ionis, impacting investor sentiment negatively. However, Ionis' plan to advance ION582 independently may offer some future potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100